Scientific Posters from ACC 09
DATA FROM GENCAROTM PHASE 3 BEST TRIAL PRESENTED AT THE AMERICAN COLLEGE OF CARDIOLOGY 58TH ANNUAL SCIENTIFIC SESSION
COMPARATIVE ANALYSIS OF FOUR BETA BLOCKER TRIALS PRESENTED AT THE AMERICAN COLLEGE OF CARDIOLOGY 58TH ANNUAL SCIENTIFIC SESSION
ARCA is currently developing Gencaro™ (tradename pending FDA approval) (bucindolol hydrochloride) for the treatment of chronic heart failure. Gencaro™ is a pharmacologically unique beta-blocker and mild vasodilator. Gencaro™ is considered part of the beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would otherwise activate the receptor. Because of its mild vasodilator effects, the Company believes Gencaro™ is well-tolerated in patients with advanced HF. ARCA has identified common genetic variations, or genetic markers, that it believes predict patient response to Gencaro™.
1 tradename is subject to FDA approval
